Transinsight and antibodies-online Develop Software for Semantic Gene and Protein Identification

Since July 2009 Transinsight GmbH and antibodies-online GmbH partner together with TU Dresden and RESprotect GmbH to develop and deploy new semantic search technologies for the Life-Science industry. Their joint efforts are funded by the THESEUS research program from the German Federal Ministry of Economics and Technology (BMWi). With only a few months into the project, the partnering companies are now able to demonstrate a first outcome of their research to the public: Research antibodies that semantically fit to genes and proteins discussed within a certain biomedical publication are automatically suggested to the reader on Transinsight's search engine www.GoPubMed.com.

"The scientist, who keeps himself up-to-date on recent biomedical publications with our knowledge-based search engine GoPubMed.com is now further supported by suggestions of semantically fitting research products for his/her specific research needs," says Dr. Michael R. Alvers, founder and CEO of Transinsight GmbH. The time consuming search for the right research antibody to a specific research question is one of the key pains in proteomics and genomics laboratories. Any simplification of this search problem, which delivers correct information instead of unhelpful, generic advertising, is welcome within the scientific community. Searching, finding and ordering the right research antibody from within a global offer of 500.000 products from more than 500 suppliers worldwide is normally a tedious work. To apply semantic, knowledge driven product recommendations to biomedical publications and thus to allow to significantly reduce the workload for the scientist always in need of research products is a truly innovative approach.

"Once the scientist has chosen a product of interest, antibodies-online GmbH takes care of all the rest, i.e. procurement of the desired products from anywhere around the world," adds Dr. Andreas Kessell, founder and managing director of antibodies-online GmbH. "Our customer is not bound to the portfolio of a single supplier but can chose from a neutral portfolio of research antibodies, that are suggested with the biomedical publications," says Dr. Kessell.

The software solution behind this innovative offer of the partnering companies Transinsight und antibodies-online is currently being developed within the THESEUS research program. Transinsight's existing semantic search platform already detects genes and proteins reliably in scientific publications and these results can be linked to the products on antibodies-online.com. "With the launch of this first prototype we managed the initial integration of the information provided on the two platforms of the partnering companies - however, the list of tasks to be taken on remains long," explains Dr. Alvers.

About antibodies-online GmbH
With more than 200.000 research antibodies offered antibodies-online GmbH is one of the leading internet marketplaces for research products worldwide. The scientific community apparently searches the internet for products that suit their research needs. On antibodies-online's websites scientists can search or browse the offer of numerous suppliers worldwide as well as order the antibody directly online, via phone or via fax. The company was founded as a spin-off of Aachen Technology University and the University Hospital of Aachen as a supplier independent German platform in April 2006. By the end of 2008 anticorps-enligne.fr, kangti-zaixian.cn and antibodies-online.com were launched as international marketplaces. Since then all listed antibodies are marketed and distributed worldwide.

About Transinsight GmbH
Transinsight develops knowledge-based semantic solutions in the Life Sciences. Their flagship products www.Go3R.org and www.GoPubMed.com, renowned biomedical search engines, are the first knowledge-based search systems of the next generation not only for the Life Sciences on the internet. In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honored with international awards i.e. the reddot design award best of the best 2009 and the German Industry Prize 2010. The firm works in close collaboration with the Dresden University of Technology. Selected customers are: Unilever, BASF, BfR, Statoil, RWE, Abcam und EMBL. For further information on Transinsight on the internet, see www.transinsight.com.

About THESEUS research program
The THESEUS research program was launched by the Federal Ministry of Economics and Technology (BMWi) in 2007 as a flagship project of the German Federal Government. As part of the program, about 60 companies, research institutes and universities are running projects to develop application-orientated basic technologies and technical standards for the internet of services. The aim is to develop new products and services for the internet. The program is scheduled to run for five years and is funded by around €100 m from the BMWi. The funds made available for research and development are being divided equally between science and economics. An additional €100 m is being contributed by interested partners in industry and research from their own funds.

Most Popular Now

Amgen and Allergan's MVASI™ (bevacizumab-awwb) and…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a bio...

Compound found in red wine opens door for new trea…

Like to unwind with a glass of red wine after a stressful day? Don't give alcohol all the credit. New research has revealed that the plant compound resveratrol, which is ...

HIV vaccine nears clinical trial following new fin…

A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar p...

Mylan and Upjohn, a division of Pfizer, to combine…

HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's o...

Leading oncologists and nutritionists pinpoint are…

An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship betwe...

Closing the door: breaking new ground related to a…

In order to sustain fast growth, cancer cells need to take up nutrients at a faster rate than healthy cells. The human glutamine transporter ASCT2 allows the amino acid g...

FDA approves first generics of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associat...

Roche and Spark Therapeutics, Inc. announce extens…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced...

FDA approves first treatment for severe hypoglycem…

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that c...

Rye is healthy, thanks to an interplay of microbes

Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribut...

GSK completes transaction with Pfizer to form new …

The Joint Venture brings together two highly complementary portfolios of trusted consumer health brands, including GSK's Sensodyne, Voltaren and Panadol and Pfizer's Advi...

Eating more plant-based foods may be linked to bet…

Eating mostly plant-based foods and fewer animal-based foods may be linked to better heart health and a lower risk of dying from a heart attack, stroke or other cardiovas...